GIP Protein (AA 22-93) (Fc Tag)

Produktnummer ABIN7274747

Produktdetails

Target: GIP (Gastric Inhibitory Polypeptide (GIP))

Protein-Typ: Recombinant

Proteineigenschaft: AA 22-93

Spezies: Human

Quelle: HEK-293 Cells

Aufreinigungstag / Konjugat: Dieses GIP Protein ist gelabelt mit Fc Tag.

Verwendungszweck: Human GIP Protein

Sequenz: Glu22-Gln93

Produktmerkmale: Recombinant Human GIP Protein is expressed from HEK293 with hFc tag at the C-Terminus.It contains Glu22-Gln93.

Reinheit: > 95 % as determined by Tris-Bis PAGE,> 95 % as determined by HPLC

Sterilität: 0.22 μm filtered

Endotoxin-Niveau: Less than 1EU per μg by the LAL method.

Biological Activity Comment: Immobilized Human GIP, hFc Tag at 0.5μg/ml (100μl/well) on the plate. Dose response curve for Biotinylated Anti-GIP Antibody, hFc Tag with the EC50 of 32.6ng/ml determined by ELISA. See testing image for detail.

Anwendungsinformationen

Beschränkungen: Nur für Forschungszwecke einsetzbar

Handhabung

Format: Lyophilized

Rekonstitution: Centrifuge the tube before opening. Reconstituting to a concentration more than 100 μg/mL is recommended. Dissolve the lyophilized protein in distilled water.

Buffer: Lyophilized from 0.22μm filtered solution in PBS ( pH 7.4). Normally 8 % trehalose is added as protectant before lyophilization.

Lagerung: -20 °C,-80 °C

Informationen zur Lagerung: -20 to -80°C for 12 months as supplied from date of receipt.,-80°C for 3-6 months after reconstitution.,2-8°C for 2-7 days after reconstitution.,Recommend to aliquot the protein into smaller quantities for optimal storage. Please minimize freeze-thaw cycles.

Haltbarkeit: 12 months

Antigendetails

Target: GIP (Gastric Inhibitory Polypeptide (GIP))

Andere Bezeichnung: GIP (GIP Produkte)

Synonyme: GIP Protein, xgip Protein, Gludins Protein, RATGLUDINS Protein, gastric inhibitory polypeptide Protein, gastric inhibitory polypeptide L homeolog Protein, GIP Protein, gip Protein, Gip Protein, gip.L Protein

Hintergrund: The potential application of glucose-dependent insulinotropic polypeptide (gastric inhibitory polypeptide, GIP) in the management of obesity and type 2 diabetes has been controversial. Initial interest in the therapeutic use of GIP was dampened by evidence that its insulinotropic activity was reduced in type 2 diabetes and by reports that it increased glucagon secretion and adipose deposition in non-diabetic individuals.

Molekulargewicht: 34.9 kDa. Due to glycosylation, the protein migrates to 40-50 kDa based on Tris-Bis PAGE result.

UniProt: P09681

Pathways: Positive Regulation of Peptide Hormone Secretion, Peptide Hormone Metabolism, Hormone Activity, Regulation of Lipid Metabolism by PPARalpha, Lipid Metabolism